ANTIKÖRPERFORMULIERUNG

European patent · EP2858671 · In force

Register entry

Publication number
EP2858671
Application number
EP13744818
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 11, 2013
Published
Apr 15, 2015
Granted
Jul 24, 2019
Protection ends at the latest
Jun 10, 2033
Next annual fee due
Jun 30, 2027
IPC classes
A61K 39/395 (2006.01)
A61K 9/00 (2006.01)
A61K 47/18 (2017.01)
A61K 47/26 (2006.01)
C07K 16/28 (2006.01)
Priority
US 201261658472 P 12.06.2012
PCT application
PCT/IB2013/054777 11.06.2013
PCT publication
WO2013/186700 19.12.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  6. Jul 24, 2019

    Granted

    Published in Swissreg on 24.07.2019

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

STARK, Christoph

4002 Basel

COSENZA, Marta

4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.